Blog
Clinical insights, research updates, and expert commentary from A/Prof Adrian Hunt.
Surfer's Eye: When a Pterygium Needs Surgery — and When It Doesn't
"Surfer's eye" is the common name for a pterygium — a growth driven by years of sun, wind, and water. Having one rarely means rushing to surgery. Here is how the decision is actually made.
Why I Usually Operate on One Eye at a Time
Can both cataracts be done at once? Some surgeons offer bilateral surgery — both eyes the same day. A/Prof Adrian Hunt explains when that is the right choice, and why for most patients he treats one eye at a time.
Insights and Highlights from the FRB! Retinal Vein Occlusion Module — ANZSRS 2026
A/Prof Adrian Hunt presented the retinal vein occlusion module of the Fight Retinal Blindness! registry session at the 2026 ANZSRS meeting in Sydney. The publications discussed in the talk are listed below, with full-text links where open access.
Retinal Vein Occlusion: What a Decade of Real-World Data Tells Us
The Autumn 2026 edition of MacularNEWS draws on the Fight Retinal Blindness! registry to explain what patients having injections for retinal vein occlusion can expect — and profiles A/Prof Adrian Hunt's work as an investigator in the registry's RVO module.
Can Injections for Retinal Vein Occlusion Ever Be Stopped?
A/Prof Adrian Hunt's latest first-author study, in the British Journal of Ophthalmology, examines which eyes with retinal vein occlusion can safely pause anti-VEGF injections — and how to recognise them.
Sunscreen Under Scrutiny — Don't Forget Your Eyes
Sunscreen efficacy has been questioned by recent TGA reviews and independent SPF testing. The conversation has mostly skipped the eyes — where a daily protection routine matters as much as any cream.
Cosmetic and Halloween Contact Lenses: Why Unregulated Lenses Put Your Eyes at Risk
The TGA is reviewing the regulation of cosmetic contact lenses in Australia. A/Prof Hunt explains the risks of unregulated lenses and what to look for if something goes wrong.
PhD Conferral — University of Sydney
A/Prof Adrian Hunt was conferred his PhD at the University of Sydney on 3 December 2025.
Ozempic and Eye Stroke: What Patients on GLP-1 Drugs Need to Know
An emerging safety signal links semaglutide (Ozempic, Wegovy) to a rare form of eye stroke called NAION. A/Prof Hunt explains what the evidence shows, what the TGA has done, and when to seek urgent eye care.
miVision — Retinal Vein Occlusion: Current and Future Management
A/Prof Hunt authored an article in miVision on the current state and future directions of retinal vein occlusion management.
How Treatment Intensity Varies in Retinal Vein Occlusion — and Why It Matters
A/Prof Hunt's research revealing how widely ophthalmologists differ in how frequently they treat retinal vein occlusion — from RANZCO Best Paper to AAO international recognition.
Switching to Faricimab for Wet Macular Degeneration — What the Evidence Shows
A/Prof Hunt's research on what happens when patients with wet AMD switch from established injections to faricimab — presented at ASRS and selected as AAO Editor's Choice.
miVision — FRB! Research: So Much More Than Number Crunching
A/Prof Hunt authored an article in miVision explaining how Fight Retinal Blindness! registry research translates into better patient care.
EURETINA 2023 — Presentation at Euretina in Amsterdam
A/Prof Hunt presented research on attempted cessation of VEGF inhibitors in retinal vein occlusion at EURETINA 2023 in Amsterdam.
HealthED Clinical Takeaway Podcast — Macular Degeneration Prevention
A/Prof Hunt was a guest on the HealthED Clinical Takeaway podcast, discussing macular degeneration prevention for GPs and primary care clinicians.
Three-Year Injection Outcomes for Central Retinal Vein Occlusion
A/Prof Hunt's research tracking CRVO patients from first injection through three years of treatment — published in Ophthalmology Retina and featured across Australasian eye-care media.
Hemiretinal Vein Occlusion — A Unique Entity That Responds Well to Treatment
A/Prof Hunt's research establishing hemiretinal vein occlusion as a distinct condition with its own treatment profile — not just a variant of branch or central RVO.
Comparing Injection Treatments for Retinal Vein Occlusion — Ranibizumab vs Aflibercept
A/Prof Hunt's research comparing the two main anti-VEGF agents for RVO — a EURETINA Prize Paper that became one of Acta Ophthalmologica's most downloaded articles.